← Back to patent-cliff list
Clobetasol propionate ophthalmic nanoemulsion (Salvat)
Tier C — Watch / tradeClobetasol propionate ophthalmic nanoemulsion (Salvat)
Salvat
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
-
Type
Targets：Steroid hormone receptor
Indications (approved)：白内障
Regional status
US
-
EU
Phase III
2022-12-12
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Clobetasol propionate ophthalmic nanoemulsion (Salvat)?
Approved indications include: 白内障.
When does the Clobetasol propionate ophthalmic nanoemulsion (Salvat) patent expire?
No public expiry year is available for Clobetasol propionate ophthalmic nanoemulsion (Salvat) yet; this page updates once verified.
How do I get a quote for Clobetasol propionate ophthalmic nanoemulsion (Salvat) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-21